.png?width=11&height=11&name=plus-img%20(1).png){kind=small}
In a case alleging that a brand name pharmaceutical company paid a generic drug maker $112 million to delay a generic version of the medication Opana, a JPML moved to consolidate six putative class actions.
“We look forward to pressing ahead with the litigation before Judge [Harry] Leinenweber on behalf of third-party payers and consumers who allege they overpaid for Opana, a critical drug used by millions to alleviate moderate to severe pain,” said co-chair of the Firm’s Antitrust and Competition Practice, Gregory Asciolla.
New York